3-Year Supporting Data on TAVI in Low-Risk Patients: EVOLUT

Published Date: 08 Mar 2023

3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery

Read Full News

Latest News

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

Lebrikizumab Benefits AD Patients With Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD Mona Shahriari, MD, FAAD, Angela Lamb, MD

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

Skin of Color Savvy: Hair-Care Challenges in Dermatology, With Amy McMichael, MD, and Kayla Taylor, MD Amy McMichael, MD, Kayla Taylor, MD

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Latest News

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

News All Time

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Potassium-enriched salt recommended for blood pressure control

The use of potassium-enriched salt has now been recommended by the National Hypertension Taskforce—Australia's peak body for blood pressure control—in a new position statement published in the Journal of Hypertension.

Chronic pain may increase risk of high blood pressure in adults

Chronic pain in adults may increase their risk of high blood pressure, and the location and extent of pain and if they also had depression were contributing factors, according to new research published today in Hypertension.

New 'heart percentile' calculator helps young adults grasp their long-term risk

A new Northwestern Medicine study introduces a first-of-its-kind online calculator that uses percentiles to help younger adults forecast and understand their risk of a heart event over the next 30 years. With rates of obesity, ...

Direct link between peak air pollution and cardiac risk revealed

In Lombardy, the risk of suffering cardiac arrest may increase on days recording high levels of air pollution. This emerges from a study conducted by the Politecnico di Milano and published in the journal Global Challenges.

Hypertension affects the brain much earlier than expected, study suggests

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators. ...

Disrupted calcium signaling can throw the heart off rhythm

A joint study by the University Medical Center Göttingen (UMG) and the University Hospital Würzburg provides new insights into why heart muscle cells lose their rhythm in atrial fibrillation. Disrupted calcium signaling ...

Common gout drug may reduce risk of heart attack and stroke

A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review.

During a heart attack, immediate stenting of other arteries isn't always necessary

A blocked coronary artery causing an acute heart attack must be opened immediately with a stent procedure. However, if other coronary arteries also appear to be narrowed, it is safe to wait and treat those later. This approach ...

New pill cuts 'bad' cholesterol by 60%, potentially replacing injections

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections.

From contraception to menopause: Why women face a higher risk of stroke

Stroke is one of the leading causes of disability worldwide. It places a huge burden on families, health systems and societies. Increasingly, strokes are not just occurring in older adults. They are affecting younger people ...

New gene discoveries improve diagnosis of inherited heart disease

Centenary Institute researchers have uncovered new genetic causes of inherited heart conditions, providing families with vital answers to guide treatment and prevention.

Very low LDL-cholesterol correlates to fewer heart problems after stroke

Brigham and Women's Hospital's TIMI Study Group reports that in patients with prior ischemic stroke, very low achieved LDL-cholesterol correlated with fewer major adverse cardiovascular events and fewer recurrent strokes, ...

Plant-based diet can prevent, reverse form of heart disease in animals with hypertension

Eating a plant-based diet consisting of fruits, vegetables, nuts and legumes can help prevent and reverse heart disease in rats that have high blood pressure, according to a study published by researchers in the Institute ...

Recommended News For You

Telehealth in the pandemic era resulted in fewer therapy interruptions.

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Year in Review: Non-Small Cell Lung Cancer

Smart exercise planning could boost recovery for people with cancer

Immunotherapy Is As Safe As Other Cancer Treatments During Pregnancy.

Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity

Recommended Articles For You

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain 

A New Dawn for Triple-Negative Breast Cancer: Emerging Therapies and the Art of Healing 

An Overview Of Leukemia Cutis: What It Is And How To Treat It 

Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radiation therapy for patients with breast cancer

2.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.

3.

Beyond What Is Visible in Myelofibrosis?

4.

Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.

5.

Future of Lab-Developed Tests Still Taking Shape

1.

Exploring the Potential of Cytologic Atypia in Cancer Diagnosis

2.

Managing High Potassium Levels: A Comprehensive Guide to Veltassa 

3.

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders

4.

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision

5.

The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

3.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

4.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot